Consolidated net sales revenue went up by an annual 20.9% to 599.4 million euro in 2023, Salus said in a filing with the Ljubljana Stock Exchange.
The group's operating profit decreased to 13.2 million euro from 16 million euro in 2022, while EBITDA totalled 18.9 million euro, down from 20.5 million euro.
Ljubljana-based Salus is one of Slovenia's leading wholesalers of pharmaceutical and medical products.
($ = 0.91413 euro)